Neurocrine Biosciences (NBIX) Current Deferred Revenue (2010 - 2017)
Neurocrine Biosciences (NBIX) posted Current Deferred Revenue of $513000.0 for Q1 2017, up 9.15% on a QoQ basis from $470000.0 in Q4 2016, and up 48.7% year-over-year from $345000.0 in Q1 2016.
Neurocrine Biosciences (NBIX) Current Deferred Revenue (2010 - 2017) Analysis & Trends
Neurocrine Biosciences' Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $513000.0 for Q1 2017.
- Quarterly Current Deferred Revenue rose 48.7% year-over-year to $513000.0 in Q1 2017, while the trailing twelve-month figure through Mar 2017 was $513000.0 (up 48.7% YoY) and the FY2016 annual result came in at $470000.0, down 95.39% from the prior year.
- Current Deferred Revenue was $513000.0 for Q1 2017 at Neurocrine Biosciences, up from $470000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $10.2 million in Q1 2015 and bottomed at $52000.0 in Q2 2014.
- A 5-year average of $1.8 million and a median of $428000.0 in 2016 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2015 — Current Deferred Revenue soared 8471.43% — and 2016, when it slumped 96.62%.
- Neurocrine Biosciences' Current Deferred Revenue stood at $730000.0 in 2013, then plunged by 83.7% to $119000.0 in 2014, then surged by 8471.43% to $10.2 million in 2015, then sank by 95.39% to $470000.0 in 2016, then increased by 9.15% to $513000.0 in 2017.
- Business Quant data shows NBIX's Current Deferred Revenue at $513000.0 in Q1 2017, $470000.0 in Q4 2016, and $428000.0 in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 513,000.00 |
| Dec 31, 2016 | 470,000.00 |
| Sep 30, 2016 | 428,000.00 |
| Jun 30, 2016 | 386,000.00 |
| Mar 31, 2016 | 345,000.00 |
| Dec 31, 2015 | 10.20 Mn |
| Sep 30, 2015 | 232,000.00 |
| Jun 30, 2015 | 197,000.00 |
| Mar 31, 2015 | 10.20 Mn |
| Dec 31, 2014 | 119,000.00 |
| Sep 30, 2014 | 85,000.00 |
| Jun 30, 2014 | 52,000.00 |
| Sep 30, 2013 | 730,000.00 |
| Jun 30, 2013 | 1.46 Mn |
| Mar 31, 2013 | 2.19 Mn |
| Dec 31, 2012 | 2.92 Mn |
| Sep 30, 2012 | 10.18 Mn |
| Jun 30, 2012 | 17.44 Mn |
| Mar 31, 2012 | 25.74 Mn |
| Dec 31, 2011 | 34.24 Mn |